Remove Cell Biology Remove Engineering Remove Marketing
article thumbnail

Levers for Biological Progress

Codon

Molecular biology has only been around for about 80 years, and tools to study biomolecules (such as DNA and RNA sequencing, or proteomics) have only existed for about half of that time. We are in the absolute infancy of molecular and cell biology, and this means there’s a lot of stuff we still don’t understand.

DNA 132
article thumbnail

Women in STEM with Juliet Williams

Drug Target Review

Shortly after finishing my studies, I landed my first job in industry working on cell biology research for several disease indications. With these newer programs, I’ve had the honour of collaborating with my team to build a multi-faceted drug discovery engine. I’ve already had a number of ‘rocking chair’ moments in my career.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Innate Pharma 2021 Financial Calendar

The Pharma Data

All financial reports are released before market open CET. Innate has been a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. . .

article thumbnail

Women in STEM July: Meet Michelle Arkin

Drug Target Review

I went to Genentech and postdoc-ed for Jim Wells in protein engineering. Prior to UCSF, Michelle was Associate Director of cell biology at Sunesis Pharmaceuticals, where she helped discover inhibitors of protein-protein interactions for IL-2/IL-2R and LFA1/ICAM (lifitegrast, marketed by Novartis).

DNA 98
article thumbnail

Innate’s First NK Cell Engager Selected by Sanofi as Drug Candidate for Development

The Pharma Data

Innate has been a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering.

Drugs 40
article thumbnail

Women in Stem with Vicky Marsh Durban

Drug Target Review

Ending up at a small start-up, which has since become Molecular Devices, I took on the challenge of commercialising new technology in an underdeveloped market. I don’t think that it’s harder for women to enter careers in STEM, at least not in the scientific field—cell biology—that I have predominantly worked in.

Doctors 59
article thumbnail

First Patient Dosed in Monalizumab Phase 3 Clinical Trial Triggers $50M Payment From AstraZeneca

The Pharma Data

Innate has been a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering.